RxDoctor Payments Data

Camile Shamblin

Nurse Practitioner · Panama City, FLNPI 1639760457

Payments from drug & device makers

$6,291in general payments, 2019–2025

Across 268 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • UCB, Inc.$829
  • AbbVie$742
  • Johnson & Johnson$557
  • Novartis$420
  • Sanofi$407
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,19298%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,291 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$27,279
Medicare patients
182
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol12$74,730
Hydroxychloroquine Sulfate167$7,199
Ibandronate Sodium77$2,414
MethotrexateMethotrexate Sodium90$1,658
Diclofenac Sodium43$1,357
Leflunomide16$976
Methylprednisolone88$639
Gabapentin22$498
Celecoxib17$468
Albuterol Sulfate HfaAlbuterol Sulfate20$440
Methocarbamol21$290
Prednisone36$270
Duloxetine Hcl11$251
Tramadol Hcl25$238
Meloxicam46$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$829$74,73012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →